Table 7.

Multivariate analysis including patients who received stereotactic radiotherapy with dose/fractionation data (n = 1739)

		Hazard Ratio	95% Confidence Interval	p-value
Sex	Male	1.00	Ref	0.001
	Female	0.82	0.73–0.92
Age	18–59	1.00	Ref	0.01
	60–69	1.12	0.97–1.29
	70–79	1.27	1.09–1.48
	80+	1.35	1.04–1.76
Comorbidity	0	1.00	Ref	0.004
	1	1.02	0.89–1.18
	> 2	1.41	1.15–1.73
Histology	Adenocarcinoma	1.00	Ref	< 0.0001
	Non-adenocarcinoma	1.29	1.14–1.45
Race	White	1.00	Ref	0.52
	Non-white	1.05	0.90–1.23
Insurance	Uninsured	1.00	Ref	0.77
	Insured	0.95	0.69–1.32
Facility Type	Academic	1.00	Ref	0.17
	Nonacademic	1.09	0.97–1.22
Systemic Therapy	Chemotherapy	1.00	Ref	0.51
	Immunotherapy	1.08	0.86–1.37
Biologically Effective Dose	≤60 Gy	1.00	Ref	< 0.0001
	> 60 Gy	0.79	0.70–0.90